Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Tanezumab 2.5 mg	1,008
Overall Study	STARTED	Tanezumab 5 mg	1,005
Overall Study	STARTED	NSAID	1,008
Overall Study	Treated	Tanezumab 2.5 mg	1,002
Overall Study	Treated	Tanezumab 5 mg	998
Overall Study	Treated	NSAID	996
Overall Study	COMPLETED	Tanezumab 2.5 mg	741
Overall Study	COMPLETED	Tanezumab 5 mg	729
Overall Study	COMPLETED	NSAID	757
Overall Study	NOT COMPLETED	Tanezumab 2.5 mg	267
Overall Study	NOT COMPLETED	Tanezumab 5 mg	276
Overall Study	NOT COMPLETED	NSAID	251

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02528188/flow